Exploiting this PI3K vulnerability has proven to be highly effective, making triple combination therapy (a CDK4/6 inhibitor, a PI3K inhibitor, and endocrine therapy) one of the most potent treatment regimens for breast cancer patients in clinical settings. Here, PIK3CA is linked to breast carcinoma.